TY - JOUR
T1 - Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register-Based Cohort Study
AU - Godtfredsen, Sissel J.
AU - Yonis, Harman
AU - Baech, Joachim
AU - Al-Hussainy, Nour R.
AU - Riddersholm, Signe
AU - Kober, Lars
AU - Schou, Morten
AU - Christensen, Jacob Haaber
AU - Hutchings, Martin
AU - Dahl-Sørensen, Rasmus Bo
AU - Kamper, Peter
AU - Dietrich, Caroline E.
AU - Andersen, Mikkel Porsborg
AU - Torp-Pedersen, Christian
AU - Sogaard, Peter
AU - El-Galaly, Tarec Christoffer
AU - Kragholm, Kristian H.
N1 - © 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2025/2
Y1 - 2025/2
N2 - Risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment is unclear. cHL patients ≥ 18 years at diagnosis treated with doxorubicin-containing chemotherapy between 2000 and 2022 were matched 1:5 with comparators on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥ 1). Cause-specific cumulative incidence of a composite of CVDs with corresponding 95% confidence intervals (CIs) were computed with death and lymphoma relapse as competing events (i.e., by censoring individuals at such occurrences) using the Aalen-Johansen estimator. A total of 1905 patients and 9525 comparators with a median follow-up of 10 years (interquartile range, [IQR]: 5.9-17.4). Median age was 39 years (IQR: 27-56), median cumulative doxorubicin dose was 250 mg/m2 (IQR: 200-300). The CVD cumulative incidences were 4.7% (95% CI: 3.6-5.7) for patients versus 2.6% (95% CI: 2.3-2.9) for comparators at 5 years, 8.9% (95% CI: 7.2-10.5) versus 5.5% (95% CI: 4.9-6.0) at 10 years, and 17.0% (95% CI: 14.1-19.9) versus 8.2% (95% CI: 7.4-9.0) at 15 years. CVD remains a substantial effect after contemporary treatment for cHL, suggesting that awareness of symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship.
AB - Risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment is unclear. cHL patients ≥ 18 years at diagnosis treated with doxorubicin-containing chemotherapy between 2000 and 2022 were matched 1:5 with comparators on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥ 1). Cause-specific cumulative incidence of a composite of CVDs with corresponding 95% confidence intervals (CIs) were computed with death and lymphoma relapse as competing events (i.e., by censoring individuals at such occurrences) using the Aalen-Johansen estimator. A total of 1905 patients and 9525 comparators with a median follow-up of 10 years (interquartile range, [IQR]: 5.9-17.4). Median age was 39 years (IQR: 27-56), median cumulative doxorubicin dose was 250 mg/m2 (IQR: 200-300). The CVD cumulative incidences were 4.7% (95% CI: 3.6-5.7) for patients versus 2.6% (95% CI: 2.3-2.9) for comparators at 5 years, 8.9% (95% CI: 7.2-10.5) versus 5.5% (95% CI: 4.9-6.0) at 10 years, and 17.0% (95% CI: 14.1-19.9) versus 8.2% (95% CI: 7.4-9.0) at 15 years. CVD remains a substantial effect after contemporary treatment for cHL, suggesting that awareness of symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship.
KW - Hodgkin lymphoma
KW - cardiotoxicity
KW - late effects of treatment
UR - http://www.scopus.com/inward/record.url?scp=85208444651&partnerID=8YFLogxK
U2 - 10.1111/ejh.14334
DO - 10.1111/ejh.14334
M3 - Journal article
C2 - 39501912
SN - 0902-4441
VL - 114
SP - 343
EP - 352
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 2
ER -